Search Within

Parisa Momtaz

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (7)
  2. Meeting Abstract (6)
Groups
  1. Center for Molecular Imaging and Biotechnology (CMIB) (13)
  2. Department of Medicine (13)
  3. Epidemiology and Biostatistics (13)
  4. GSK Faculty (13)
  5. Human Oncology and Pathogenesis Program (13)
  6. Melanoma Disease Management Team (13)

More Groups

People
  1. Nikolaus Schultz (8)
  2. Alexander Shoushtari (6)
  3. David Solit (6)
  4. Elizabeth Won (6)
  5. David Kelsen (5)
  6. Geoffrey Ku (5)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (1)
  4. 2021 (2)
  5. 2020 (1)
  6. 2019 (3)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Clinical Cancer Research (2)
  3. Nature (2)
  4. Annals of Oncology (1)
  5. Cancer (1)
  6. JCO Precision Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (6)
  2. American Association for Cancer Research (2)
  3. Nature Publishing Group (2)
  4. Elsevier Science, Inc. (1)
  5. Oxford University Press (1)
  6. Wiley Blackwell (1)

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
    Journal Article

    Sethna, Z.; Guasp, P.; Reiche, C.; Milighetti, M.; Ceglia, N.; Patterson, E.; Lihm, J.; Payne, G.; Lyudovyk, O.; Rojas, L. A.; more...
    Nature (2025)

    Fulltext@MSK | Save
  • Germline pathogenic variants in a large convenience cohort of multiple melanoma subtypes
    Meeting Abstract

    Lochrin, S. E.; Kemel, Y.; Stuart, J.; Smithy, J. W.; Mandelker, D.; Momtaz, P.; Chatila, W. K.; Schultz, N.; Postow, M. A.; Stadler, Z. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Early on-treatment assessment of T cells, cytokines, and tumor DNA with adaptively dosed nivolumab + ipilimumab: Final results from the phase 2 ADAPT-IT study
    Journal Article

    Smithy, J. W.; Kalvin, H. L.; Ehrich, F. D.; Shah, R.; Adamow, M.; Raber, V.; Maher, C. A.; Kleman, J.; McIntyre, D. A. G.; Shoushtari, A. N.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
    Journal Article

    Rojas, L. A.; Sethna, Z.; Soares, K. C.; Olcese, C.; Pang, N.; Patterson, E.; Lihm, J.; Ceglia, N.; Guasp, P.; Chu, A.; more...
    Nature (2023)

    Fulltext@MSK | Save
  • Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes
    Journal Article

    Momtaz, P.; O'Connor, C. A.; Chou, J. F.; Capanu, M.; Park, W.; Bandlamudi, C.; Berger, M. F.; Kelsen, D. P.; Suehnholz, S. P.; Chakravarty, D.; more...
    Cancer (2021)

    Fulltext@MSK | Save
  • Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas
    Journal Article

    Shoushtari, A. N.; Chatila, W. K.; Arora, A.; Sanchez-Vega, F.; Kantheti, H. S.; Rojas Zamalloa, J. A.; Krieger, P.; Callahan, M. K.; Betof Warner, A.; Postow, M. A.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S. B.; Chou, J. F.; Gabler, A.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O-) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA)
    Meeting Abstract

    Janjigian, Y. Y.; Chou, J. F.; Simmons, M.; Momtaz, P.; Sanchez-Vega, F.; Shcherba, M.; Ku, G. Y.; Won, E.; Chong, C. R.; Gerdes, H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save